Apexigen Valuation
| APGNDelisted Stock | USD 0.43 0.01 2.27% |
Apexigen is overvalued. Apexigen shows a prevailing Real Value of $0.38 per share. The current price of the firm is $0.43. Our model approximates the value of Apexigen from analyzing the firm fundamentals such as return on equity of -15.98, and Current Valuation of 205.33 K as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Apexigen's price fluctuation is very steady at this time. Calculation of the real value of Apexigen is based on 3 months time horizon. Increasing Apexigen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Apexigen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Apexigen Stock. However, Apexigen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.43 | Real 0.38 | Hype 0.43 | Naive 0.42 |
The intrinsic value of Apexigen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Apexigen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Apexigen helps investors to forecast how Apexigen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Apexigen more accurately as focusing exclusively on Apexigen's fundamentals will not take into account other important factors: Apexigen Total Value Analysis
Apexigen is presently forecasted to have valuation of 205.33 K with market capitalization of 9.57 M, debt of 106 K, and cash on hands of 21.62 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Apexigen fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
205.33 K | 9.57 M | 106 K | 21.62 M |
Apexigen Asset Utilization
One of the ways to look at asset utilization of Apexigen is to check how much profit was generated for every dollar of assets it reports. Apexigen shows a negative utilization of assets of -0.89 percent, losing $0.00894 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Apexigen shows how unproductive it operates for each dollar spent on its assets.Apexigen Ownership Allocation
Apexigen holds a total of 24.86 Million outstanding shares. Apexigen shows 8.81 percent of its outstanding shares held by insiders and 13.54 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Apexigen Profitability Analysis
Net Loss for the year was (32.07 M) with profit before overhead, payroll, taxes, and interest of 0.About Apexigen Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Apexigen. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Apexigen based exclusively on its fundamental and basic technical indicators. By analyzing Apexigen's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Apexigen's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Apexigen. We calculate exposure to Apexigen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Apexigen's related companies.Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. The company was founded in 2010 and is based in San Carlos, California. Apexigen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
Apexigen Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 19.8 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Apexigen Stock
If you are still planning to invest in Apexigen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Apexigen's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |